Our primary comparison between Tirzepatide and Semaglutide yielded 25,060 matched pairs, while other treatment comparisons produced cohorts of varying sizes, from 7240 pairs for Tirzepatide versus Naltrexone/Bupropion to 18,892 pairs for Tirzepatide versus Phentermine (Fig
These results are parallel to, and consistent with, the aforementioned effects on insulin
In fact, some research shows that up to 60% of weight lost on GLP-1s can come from lean mass rather than fat
Be aware of risks like low blood sugar and thyroid issues
#cancer #research To view or add a comment, sign in This new editorial in Supportive Care in Cancer by Siobhn Gaynor, patient advocate, and Professor Seamus OReilly, Clinical Lead at Cancer Trials Ireland, with co-author Dr Erica Mayer, calls for a stronger focus on quality of life and the patient perspective when assessing cancer therapies